Ocugen, Inc. (OCGN) - 10-Q Summary for Period Ended June 30, 2026
Business Context and Reporting Period
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene therapies for retinal diseases. The company operates as a single segment. This report covers the quarterly period ended June 30, 2026. The company is currently in the clinical development phase for its primary candidates, OCU400 (retinitis pigmentosa) and OCU410ST (Stargardt disease), with no commercial product revenue generated to date.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | YTD 2026 (6 Months) | Q2 2025 (3 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Total Revenue | $1.49 million | $3.02 million | $1.37 million | $2.85 million |
| Net Loss | $(24.88) million | $(44.05) million | $(14.74) million | $(30.09) million |
| Net Loss Per Share (Basic/Diluted) | $(0.07) | $(0.13) | $(0.05) | $(0.10) |
| Operating Expenses | $17.93 million | $37.30 million | $15.17 million | $31.15 million |
| Cash and Cash Equivalents (End of Period) | $100.05 million | Balance Sheet Data | ||
| Total Debt (Convertible Notes + Long Term) | $84.09 million | Balance Sheet Data |
Note: Revenue is derived entirely from collaborative arrangements (CanSinoBIO). The company has an accumulated deficit of $452.1 million as of June 30, 2026.
Material Changes vs. Prior Period
- Financing Activity: In May 2026, the company issued $130.0 million in 6.75% Convertible Senior Notes due 2034, generating net proceeds of approximately $112.5 million. In January 2026, it raised $20.7 million via a registered direct offering, and in March 2026, received $14.2 million from warrant exercises.
- Debt Restructuring: Proceeds from the Convertible Notes were used to fully repay the $32.7 million Avenue Capital Loan, resulting in a $2.38 million loss on extinguishment of debt.
- Derivative Liability: The issuance of Convertible Notes created a new derivative liability of $33.7 million, resulting in a $1.89 million loss due to changes in fair value during the quarter.
- Expense Growth: Research and Development (R&D) expenses increased by $2.3 million in Q2 2026 compared to Q2 2025, driven by personnel costs and clinical trial expenses for OCU410ST. General and Administrative (G&A) expenses increased by $0.5 million.
- Liquidity: Cash and cash equivalents increased significantly from $18.6 million at year-end 2025 to $100.1 million at June 30, 2026, due to the financing activities described above.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: Management has concluded there is substantial doubt about the company's ability to continue as a going concern within one year of the report date. This is due to recurring operating losses, negative cash flows from operations, and the need for significant future funding to support clinical trials and commercialization.
- Clinical Milestones:
- OCU400: Phase 3 trial (liMeliGhT) enrollment is complete. Topline data is expected in Q1 2027, with a potential BLA submission in Q4 2027.
- OCU410ST: Dosing in the Phase 2/3 pivotal trial (GARDian3) was completed in April 2026. A BLA submission is planned for mid-2027.
- OCU410: FDA granted RMAT designation in July 2026. Phase 3 trial (ArMaDa3) initiation is planned for late Q3 2026.
- Legal Proceedings: The company is involved in multiple securities class action and derivative lawsuits. A Delaware Court recently validated the company's charter amendment regarding authorized shares, dismissing one class action as moot, but appeals in other jurisdictions remain pending.
- Convertible Note Terms: The new notes are not convertible until May 15, 2027, or the "Reserved Share Effective Date." Until stockholder approval is obtained (scheduled for September 21, 2026), conversions must be settled in cash, and the notes are classified as current liabilities.
Investor Verification Checklist
- Going Concern Status: Verify the company's ability to secure additional capital beyond the current $100 million cash balance to fund operations through 2027 and beyond.
- Convertible Note Conversion: Monitor the September 21, 2026 shareholder meeting for approval of the authorized share increase required to allow physical settlement of the Convertible Notes.
- Clinical Trial Data: Track the release of topline data for the OCU400 Phase 3 trial (expected Q1 2027) and the OCU410ST Phase 2/3 trial (expected mid-2027).
- Legal Outcomes: Monitor the status of the Third Circuit appeal regarding the securities class action lawsuit and any potential financial impact from legal settlements.
- Derivative Liability Volatility: Assess the impact of stock price volatility on the quarterly fair value adjustments of the $33.7 million derivative liability.